PT-141
Also known as: Bremelanotide, Vyleesi
Key Facts: PT-141
- Category
- Sexual Health
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - HSDD in premenopausal women
- Administration
- Subcutaneous injection (autoinjector available)
- Typical Dose
- 1.75 mg as needed
- Frequency
- As needed, at least 45 min before activity
- Evidence Level
- FDA Approved
- Duration
- As needed, at least 45 min before activity
What to Expect
An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Derived from Melanotan II research.
Mechanism of Action
PT-141 activates melanocortin receptors, particularly MC4R in the central nervous system. Unlike PDE5 inhibitors that work on blood flow, PT-141 works through the brain's sexual arousal pathways, affecting desire and arousal centrally.
Research Summary
FDA approval based on trials showing significant improvement in desire and distress scores in women with HSDD. Also studied for male erectile dysfunction with positive results. Works through a novel mechanism compared to existing ED treatments.
Dosing Information
Typical Dosingⓘ
Community experience
1.75 mg as needed
0.5-2 mg per dose
As needed, at least 45 min before activity
FDA-approved dose is 1.75 mg. Not for daily use - max 8 doses per month. Can cause nausea and flushing.
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
1.75 mg (FDA approved for women)
Research doses for men varied
Duration
As needed, at least 45 min before activity
Administration
Subcutaneous injection (autoinjector available)
Timing & Administration
Best Time to Take
1-2 hours before sexual activity
As needed, max once per 24 hours
Food Recommendation
With or without food
Why This Timing?
PT-141 (Bremelanotide) takes 45-60 minutes to work. Timing before anticipated activity is optimal.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Nausea (40% - most common)
- ●Facial flushing (20%)
- ●Injection site reactions
- ●Headache
- ●Transient blood pressure increase
- ●Skin hyperpigmentation with frequent use
- ●Vomiting
- ●Fatigue
- ●FDA approved (Vyleesi) for HSDD in women
References
Related Peptides
Peptides commonly compared with PT-141 or used in similar applications.
Melanotan II
ResearchA synthetic analog of alpha-melanocyte stimulating hormone (α-MSH). Known for inducing skin tanning and having effects on libido and sexual function.
Sexual HealthSemaglutide
FDAA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. One of the most effective pharmaceutical weight loss interventions available.
Weight LossLiraglutide
FDAAn FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.
Weight LossOxytocin
FDAA naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.
HormonalMK-677
Clinical TrialsAn orally active growth hormone secretagogue that mimics ghrelin. Not a peptide technically, but frequently discussed alongside GH peptides due to similar effects.
Growth HormoneSelank
Clinical TrialsA synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.
CognitiveWant updates on PT-141 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.